U.S. Markets open in 6 hrs 39 mins

Tetraphase Pharmaceuticals’ (TTPH) Buy Rating Reaffirmed at HC Wainwright

The Cerbat Gem

Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday. They currently have a $17.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 191.10% from the stock’s current price. A number of other research analysts have also recently weighed in on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Piper Jaffray Companies started coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They issued an “overweight”